Company intelligence / Profile preview
ReIGNITE Therapeutics
San Francisco/San Mateo area*, California, United Statesreignitetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ReIGNITE Therapeutics is developing next-generation systemic high-capacity viral vectors for the in vivo delivery of oncolytic immunotherapies and gene therapies. Their proprietary platform leverages directed evolution to engineer vectors with large payload capacity (~50 kB) and tissue-specific tropism. No clinical results or active clinical trials are publicly reported as of June 2025.
- Therapeutic areas
- Rare DiseasesOncology
- Modalities
- Viral vectorGene therapyOncolytic virus therapyImmunotherapy (via viral vectors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on ReIGNITE Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReIGNITE Therapeutics.